Rapid Reliable Simple
Individually packed tests
Disposable pipettes(for cassette)
Package insert
Specimen: Urine

Introduction:

Urine based screening tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The speed and sensitivity of immunoassays have made them the most widely accepted method for screening urine for drugs of abuse.The DOA Cassettes / Panels are based on the principle of the highly specific immunochemical reactions of antigens and antibodies, which are used for the analysis of specific compounds in human urine. The DOA Screen Panels are rapid, visual, competitive panel immunoassay that can be used for the simultaneous, qualitative detection of 11-nor-9-tetrahydrocannabinol-9-carboxylic acid, Benzoylecgonine, Phencyclidine, Morphine, Methadone, Methamphetamine, Amphetamine, Barbiturates, Oxazepam, Nortriptyline, MDMA, Buprenorphine-3-D-Glucuronide and EDDP in urine. The length of time following drug use for which a positive result may occur is dependent upon several factors including the frequency and amount of drug, metabolic rate, excretion rate, drug half-life, and the drug user’s age, weight, activity and diet. Each drug is detected and cleared by the body at different rates.

Intended use:

The DOA Cassettes / Panels are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to fourteen of the following drugs in a variety of combinations in human urine. The designed cutoff concentrations and direct calibrator for these drugs are as follows:
Parameter        Calibrator        Cut-off(ng/mL)
THC        11-nor-9-THC-9-COOH        50 ng/ml
COC        Benzoylecgonine        300 ng/ml
PCP        Phencyclidine        25 ng/ml
OPI        Morphine        2000 ng/ml
MET        Methamphetamine        1000 ng/ml
MTD        Methadone        300 ng/ml
AMP        Amphetamine        1000 ng/ml
BAR        Secobarbital        300 ng/ml
BZO        Oxazepam        300 ng/ml
TCA        Nortriptyline        1000 ng/ml
MDMA        3,4-Methylenediioxy-MET        500 ng/ml
BUP        BUP-3-D-Glucuronide        10 ng/ml
EDDP        EDDP        100 ng/ml
OPI/MOR        Morphine        300 ng/ml

• The kit should be stored at 2-30°C until the expiry date printed on the sealed pouch.
• The test must remain in the sealed pouch until use.
• Do not freeze.
• Care should be taken to protect the components of the kit from contamination. Do not use if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.

Materials Provided:
• Individually packed tests
• Disposable pipettes(for cassette) 
• Package insert

Specimen: Urine

Principle:

The DOA Cassettes / Panels are one-step immunoassay in which chemically labeled drugs (drug-protein conjugates) compete for limited antibody binding sites with drugs which may be present in urine. The test device contains membrane strips which are pre-coated with drug-protein conjugates on the test band(s). Each strip, the drug antibody-colloidal gold conjugate pad is placed at one end of the membrane. In the absence of drug in the urine, the solution of the colored antibody-colloidal gold conjugate move along with the sample solution upward chromatographically by capillary action across the membrane to the immobilized drug-protein conjugate zone on the test band region. The colored antibody-gold conjugate then attach to the drug-protein conjugates to form visible lines as the antibody complex with the drug conjugate. Therefore, the formation of the visible precipitant in the test zone occurs when the test urine is negative for the drug. When the drug is present in the urine, the drug/metabolite antigen competes with drug-protein conjugate on the test band region for the limited antibody.  When a sufficient concentration of the drug is present, it will fill the limited antibody binding sites. This will prevent attachment of the colored antibody (drug-protein conjugate)-colloidal gold conjugate to the drug-protein conjugate zone on the test band region. Therefore, absence of the color band on the test region indicates a positive result.

A control band with a different antigen/antibody reaction is added to the immunochromatographic membrane strip at the control region (C) to indicate that the test has performed properly. This control line should always appear regardless of the presence of drug or metabolite. If the control line does not appear the test device should be discarded.